Ipamorelin vs Hexarelin

Ipamorelin was synthesized by researchers at Novo Nordisk in the late 1990s as part of a program to find GH-releasing peptides with greater receptor selectivity than the first-generation compounds GHRP-2 and GHRP-6. The result was a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds the GHS-R1a receptor with high affinity but produces substantially less stimulation of the hypothalamic-pituitary-adrenal axis than earlier GHRPs. In direct comparison studies with GHRP-2 and GHRP-6, Ipamorelin produced equivalent GH pulse amplification while generating significantly less cortisol and ACTH co-secretion. This selectivity makes it valuable as a research tool when investigators want to study the GH axis in isolation without adrenal confounders. Ipamorelin's IGF-1 elevation in animal models is consistent with its GH-stimulating activity. It's almost always studied in combination with a GHRH analog (CJC-1295 or Tesamorelin), since the GHS-R1a and GHRH receptor pathways are synergistic. The combination produces additive to supraadditive GH release compared to either compound alone, and this dual-receptor approach has become the standard GHRP research protocol design.

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide GHRP developed in the early 1990s with a potency profile that exceeds most compounds in its class for raw GH release amplitude. Where Ipamorelin is valued for selectivity, Hexarelin is valued for potency. In preclinical dose-response studies, Hexarelin produces among the highest GH release of any synthetic GHRP, though this comes with co-stimulation of cortisol and prolactin secretion, limiting its utility in research designs where adrenal axis isolation is important. The more distinctive feature of Hexarelin in the research literature is its documented GH-independent cardiovascular activity. In cardiac ischemia models, Hexarelin has been shown to produce cardioprotective effects that persist even when GH receptor signaling is blocked or absent. This has been attributed to direct activity at the CD36 receptor in cardiac tissue and possibly GHS-R1b or related receptors expressed in the heart and vasculature. Studies in rodent models of heart failure and post-myocardial infarction have documented Hexarelin reducing cardiac cell apoptosis, preserving ejection fraction, and modulating fibrotic remodeling independent of GH signaling. This dual profile, potent GH secretagogue activity plus cardiac receptor activity, makes Hexarelin a compound of interest in cardiovascular biology research that goes beyond the typical GH secretagogue model.